Ace Report Cover
Nabiximol effective and safe in managing spasticity in patients with refractory MS
Reprints
Cite This
Reprints
Cite This
AceReport Image
Cannabis
Nabiximol effective and safe in managing spasticity in patients with refractory MS
Neurol Res. 2010 Jun;32(5):451-9. doi: 10.1179/016164109X12590518685660

337 patients diagnosed with multiple sclerosis (MS) and inadequately managed by current medications were randomly assigned to receive either nabiximols, a mixture of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), or placebo through oromucosal spray for 14 weeks. Patients were assessed on mean change in spasticity from baseline measured by the 0-10 Numerical Rating Scale (NRS), the proportion of responders (≥30% improvement in NRS), the time taken to achieve ≥30% improvement in NRS, the incidence of adverse events, and various other functional outcomes. A per-protocol analysis of the results suggests that nabiximols was safe and effective in reducing spasticity and improving certain functional outcomes, while the intent-to-treat analysis did not demonstrate a significant difference between treatment with nabiximols and placebo.

Unlock the full article

Get unlimited access to OrthoEvidence with a free trial
Start Trial

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or continue reading this full article
Register Now
AskOE
Search
Close Search Window
Welcome Back!
Forgot Password?
Create an Account

Account will be affiliated with


OR
Forgot Password?

OR
Check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see the email, please check your spam or junk folder.

For further assistance, contact our support team.

Cite this Ace Report

OrthoEvidence. Nabiximol effective and safe in managing spasticity in patients with refractory MS. ACE Report. 2018;8(9):10. Available from: https://myorthoevidence.com/AceReport/Report/

Copy Citation
Share this Ace Report